암 생검 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Cancer Biopsy Market size is expected to reach USD 117.30 Billion in 2034 from USD 42.40 Billion (2025) growing at a CAGR of 11.97% during 2026-2034.

The global cancer biopsy market is witnessing substantial growth due to the increasing prevalence of cancer and the rising importance of early disease diagnosis. Biopsy procedures are essential for confirming cancer diagnoses and determining appropriate treatment strategies. With growing awareness about cancer screening and the rising adoption of minimally invasive diagnostic procedures, healthcare providers are increasingly relying on advanced biopsy techniques to improve diagnostic accuracy and patient outcomes.

Several factors are driving the growth of this market, including advancements in imaging technologies, the development of liquid biopsy techniques, and increasing investments in oncology research. Liquid biopsy, in particular, has gained attention as it allows the detection of cancer biomarkers through blood samples, reducing the need for invasive procedures. Additionally, the growing adoption of precision medicine and personalized cancer treatment approaches is increasing the demand for reliable biopsy diagnostics.

The future of the cancer biopsy market looks promising as technological innovations continue to transform cancer diagnostics. Emerging diagnostic technologies, integration of artificial intelligence in pathology, and improved biomarker detection methods are expected to enhance diagnostic capabilities. With increasing healthcare expenditure and government initiatives promoting early cancer detection programs, the market is expected to experience significant growth in the coming years.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Platforms & Instruments
• Kits & Reagents
• Services

By Type

• Tissue Biopsies
• Liquid Biopsies
• Others

By Application

• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Lung Cancer
• Prostate Cancer
• Skin Cancer
• Blood Cancer
• Kidney Cancer
• Liver Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Others

COMPANIES PROFILED

• Abbott Laboratories, Becton, Dickinson and Company, F HoffmannLa Roche Ltd, Hologic Inc, Danaher Corporation, Thermo Fisher Scientific Inc, Agilent Technologies Inc, lllumina Inc, Siemens Healthineers, GE Healthcare, BioRad Laboratories Inc, Olympus Corporation, Qiagen
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER BIOPSY MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Platforms & Instruments Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Kits & Reagents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER BIOPSY MARKET: BY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Tissue Biopsies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Liquid Biopsies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER BIOPSY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Skin Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Blood Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Kidney Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Liver Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Pancreatic Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Ovarian Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER BIOPSY MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Type
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Type
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Type
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Type
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Type
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER BIOPSY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott Laboratories
  • 9.2.2 Becton
  • 9.2.3 Dickinson And Company
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Hologic Inc
  • 9.2.6 Danaher Corporation
  • 9.2.7 Thermo Fisher Scientific Inc
  • 9.2.8 Agilent Technologies Inc
  • 9.2.9 Lllumina Inc
  • 9.2.10 Siemens Healthineers
  • 9.2.11 GE Healthcare
  • 9.2.12 Bio-Rad Laboratories Inc
  • 9.2.13 Olympus Corporation
  • 9.2.14 Qiagen